Walleye Capital
VRDN icon

Walleye Capital’s Viridian Therapeutics VRDN Stock Holding History

Walleye Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-54,398
Closed -$1.06M – 5200
2026
Q1 		$1.06M Sell
54,398
-6,444
-11% -$191K ﹤0.01% 2023
2025
Q4 		$1.89M Buy
60,842
+10,199
+20% +$280K 0.01% 1919
2025
Q3 		$1.09M Sell
50,643
-13,913
-22% -$251K ﹤0.01% 2019
2025
Q2 		$902K Sell
64,556
-39,461
-38% -$536K ﹤0.01% 2136
2025
Q1 		$1.4M Sell
104,017
-377,622
-78% -$6.43M 0.01% 1709
2024
Q4 		$9.23M Sell
481,639
-78,368
-14% -$1.7M 0.02% 679
2024
Q3 		$12.7M Buy
560,007
+129,411
+30% +$2.12M 0.03% 563
2024
Q2 		$5.6M Buy
430,596
+424,960
+7,540% +$5.88M 0.01% 1206
2024
Q1 		$98.7K Sell
5,636
-235,775
-98% -$4.57M ﹤0.01% 4401
2023
Q4 		$5.26M Buy
241,411
+227,881
+1,684% +$3.6M 0.01% 1078
2023
Q3 		$208K Sell
13,530
-73,590
-84% -$1.4M ﹤0.01% 3528
2023
Q2 		$2.07M Sell
87,120
-29,537
-25% -$758K 0.01% 1298
2023
Q1 		$2.97M Buy
116,657
+70,515
+153% +$2.26M 0.04% 505
2022
Q4 		$1.35M Sell
46,142
-143,387
-76% -$3.3M 0.02% 805
2022
Q3 		$3.89M Buy
189,529
+11,078
+6% +$199K 0.07% 288
2022
Q2 		$2.06M Buy
178,451
+16,170
+10% +$217K 0.06% 358
2022
Q1 		$3M Buy
162,281
+52,106
+47% +$1M 0.08% 257
2021
Q4 		$2.18M Buy
110,175
+87,674
+390% +$1.63M 0.07% 311
2021
Q3 		$370K Buy
+22,501
New +$330K 0.01% 925

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Walleye Capital's VRDN Position: Q2 2026 in Review

Walleye Capital sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 54,398 shares — an estimated $1.06M sold.

Walleye Capital first reported a position in VRDN in Q3 2021 and held it in 19 quarters. The position peaked at $12.7M in Q3 2024. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Walleye Capital reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 54,398 Viridian Therapeutics shares in Q2 2026, an estimated $1.06M.
  • Walleye Capital first reported a position in Viridian Therapeutics in Q3 2021 and held it in 19 quarters.
  • Walleye Capital's Viridian Therapeutics position peaked at $12.7M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.